Sanofi (SNY) |
| 44.25 0.14 (0.32%) 06-12 16:00 |
| Open: | 44.1 |
| High: | 44.505 |
| Low: | 44.02 |
| Volume: | 1,557,893 |
| Market Cap: | 106,389(M) |
| PE Ratio: | 19.41 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 52.84 |
| Resistance 1: | 45.24 |
| Pivot price: | 43.93 |
| Support 1: | 43.41 |
| Support 2: | 42.28 |
| 52w High: | 52.68 |
| 52w Low: | 42.28 |
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
| EPS | 2.300 |
| Book Value | 34.890 |
| PEG Ratio | 3.84 |
| Gross Profit | 14.335 |
| Profit Margin (%) | 15.95 |
| Operating Margin (%) | 20.00 |
| Return on Assets (ttm) | 4.7 |
| Return on Equity (ttm) | 6.6 |
Fri, 12 Jun 2026
Strong Buy Rating on Sanofi (SNY) Following Positive Study Resul - GuruFocus
Fri, 12 Jun 2026
Sanofi (NASDAQ: SNY) launches employee stock plan, wins Sarclisa EU nod, stops CIDP trial - Stock Titan
Thu, 11 Jun 2026
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Wed, 10 Jun 2026
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
Wed, 10 Jun 2026
Sanofi (SNY) Halts Study, Analyst Says Dianthus Selloff Overstat - GuruFocus
Wed, 10 Jun 2026
Dianthus drops as Sanofi halts trial for peer drug (DNTH) - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |